Instil Bio

Instil Bio

TIL

Instil Bio is a biotechnology company dedicated to discovering and developing novel therapies, with a leadership team possessing deep experience in biopharma investment and company building. The company's strategy appears to involve leveraging its leadership's network and expertise to identify and advance promising therapeutic candidates. Key executives have backgrounds in successful ventures such as Peloton Therapeutics and TCR2 Therapeutics, indicating a focus on high-potential oncology and cell therapy assets.

TIL · Stock Price

USD 8.60-10.76 (-55.58%)
Market Cap: $58.3M

Historical price data

AI Company Overview

Instil Bio is a biotechnology company dedicated to discovering and developing novel therapies, with a leadership team possessing deep experience in biopharma investment and company building. The company's strategy appears to involve leveraging its leadership's network and expertise to identify and advance promising therapeutic candidates. Key executives have backgrounds in successful ventures such as Peloton Therapeutics and TCR2 Therapeutics, indicating a focus on high-potential oncology and cell therapy assets.

OncologyImmunology

Technology Platform

The company's model appears to be based on business development and strategic asset selection expertise rather than a specific technological platform.

Pipeline

4
4 drugs in pipeline
DrugIndicationStageWatch
ITIL-168Advanced Cutaneous MelanomaPhase 2
AXN-2510Solid Tumor, AdultPhase 1
ITIL-306Epithelial Ovarian CancerPhase 1
ITIL-168Cervical CancerPhase 1

Opportunities

Opportunities lie in leveraging the leadership's strong network to in-license or acquire promising mid-stage oncology or cell therapy assets that are undervalued or lack development resources.
Successfully advancing a single asset to a proof-of-concept milestone could significantly increase company valuation.

Risk Factors

Key risks include a lack of a disclosed pipeline, creating high uncertainty; dependence on the small leadership team for deal sourcing and execution; and potential challenges in raising sufficient capital as a micro-cap public company to fund meaningful clinical development.

Competitive Landscape

Instil Bio competes with other biotech accelerators, venture capital firms, and the business development divisions of large pharma for attractive development-stage assets. Its main differentiation is the specific investment and operational experience of its CEO and board in the immuno-oncology and cell therapy space.